ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 102 citations in OpenAlex.
- Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.Blood · 2013Trial
- Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Trial
- Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.Blood advances · 2026Article
- Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant.Transplantation and cellular therapy · 2025Article
- Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.International journal of molecular sciences · 2025Article
- Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.British journal of haematology · 2025Article
- Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy.European journal of haematology · 2025Review
- Temporal dynamics of gene and protein signatures following volumetric muscle loss.Frontiers in cell and developmental biology · 2025Article
- TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors.Scientific reports · 2024Article
- Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?Mediterranean journal of hematology and infectious diseases · 2024Review
- The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.Pharmacogenomics and personalized medicine · 2024Review
- Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- The Oncogenic Role of Cyclin-Dependent Kinase Inhibitor 2C in Lower-Grade Glioma.Journal of molecular neuroscience : MN · 2023Article
- Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.Annals of hematology · 2022Review
- Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.Leukemia · 2022Article
- Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.Nature communications · 2022Article
- Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy.Annals of hematology · 2022Article
- The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.Frontiers in oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeDeletions of chromosome 1 have been described in 7% to 40% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high-resolution techniques to define the role of CDKN2C in primary patient material. EXPERIMENTAL
designWe analyzed 515 cases of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma using fluorescence in situ hybridization (FISH) for deletions of CDKN2C. In 78 myeloma cases, we carried out Affymetrix single nucleotide polymorphism mapping and U133 Plus 2.0 expression arrays. In addition, we did mutation, methylation, and Western blotting analysis.
resultsBy FISH we identified deletion of 1p32.3 (CDKN2C) in 3 of 66 MGUS (4.5%), 4 of 39 SMM (10.3%), and 55 of 369 multiple myeloma cases (15%). We examined the impact of copy number change at CDKN2C on overall survival (OS), and found that the cases with either hemizygous or homozygous deletion of CDKN2C had a worse OS compared with cases that were intact at this region (22 months versus 38 months; P = 0.003). Using gene mapping we identified three homozygous deletions at 1p32.3, containing CDKN2C, all of which lacked expression of CDKN2C. Cases with homozygous deletions of CDKN2C were the most proliferative myelomas, defined by an expression-based proliferation index, consistent with its biological function as a cyclin-dependent kinase inhibitor.
conclusionsOur results suggest that deletions of CDKN2C are important in the progression and clinical outcome of myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.